Mechanistic insights in mitral valve prolapse and associated left ventricular remodelling: Barlow*s Disease versus Fibroelastic Deficiency

• Conditions: 10046973; bulging mitral valve; mitral valve prolapse; 10007510

• Registration Number: NL-OMON52184
• Lead Sponsor: niversitair Ziekenhuis Antwerpen - Universiteit Antwerpen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

* Non syndromal mitral valve prolapse
* Age 18-80 years old
* Legally and mentally competent to sign informed consent

Exclusion Criteria

* History of cardiac surgery
* Concomitant valve disease (moderate - severe)
* Ischaemic heart disease
* Hypertrophic cardiomyopathy
* Intra-cardiac device
* History of myocarditis
* Left bundle branch block
* Chronic kidney disease stage 4-5
* Pregnancy

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Difference in left ventricular volume and function, prolapse volume and mitral<br /><br>regurgitant volume in patients with Barlow's Disease versus Fibroelastic<br /><br>Deficiency, measured by echocardiography and cardiac magnetic resonance<br /><br>imaging. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1) Difference in genetic variants (incl. cardiomyopathy and mitral valve<br /><br>prolapse genes genes) in patients with Barlow's Disease versus Fibroelastic<br /><br>Deficiency<br /><br>2) Difference in ventricular arrhythmias (incl. ventricular ectopy,<br /><br>(non)sustained ventricular tachycardia, ventricular fibrillation and sudden<br /><br>cardiac death) in patients with Barlow's Disease versus Fibroelastic Deficiency<br /><br>and association with left ventricular fibrosis (detected by cardiac magnetic<br /><br>resonance late gadolinium enhancement)</p><br>